Cardiology On -line
Home Page
Welcome Note
Scientific Committees
Timetable
Program Topics to
Include
Preliminary Program
Invitation to Exhibit
General Information
Accommodation
Accommodation Form
Registration Form
Guidelines for
Submission of 
Abstracts& Abstract Form

EXTENDED ABSTRACT DEADLINE: MARCH 30, 2001

Abstract(s) may also be submitted via this website.

1. The entire abstract (250 words) including title author(s) institution and country must fit WITHIN THE RECTANGLE. White paper of the same dimensions (5in x 7in or 13cm x 18cm) may be used. Abstracts must be typed in English.

2. The abstract should be as informative as possible:
a) state specific object of study 
b) state method used, if pertinent
c) summarize results obtained 
d) state conclusions reached

3. Type using a laser or high quality printer with a minimum font size of 10pt.

4. Standard abbreviations may be used.

5. Abstracts accepted for presentation will be published in the Abstract Book exactly as submitted; therefore abstracts must be camera-ready. Avoid errors, corrections and misspellings.

6. Send abstracts (original and 2 copies) to:

Asher Kimchi, M.D., Chairman
2nd International Congress on Heart Disease
PO Box 17659, Beverly Hills, CA 90209, USA
Tel: +1 310 657 8777
Fax: +1 310 275 8922.

7. DISCLOSURE OF FACULTY RELATIONSHIPS

Policy Statement
The International Academy of Cardiology requires that audiences at the Academy's educational programs be informed of a presenter's (moderators, speakers, faculty, authors and contributors) academic and professional affiliations, as well as other commercial relationships relevant to the content of the material that is presented.
The policy allows the listener/attendee to be fully informed in evaluating the information being presented. The situations may include, but are not limited to 1) stock options or bond holdings in a for-profit corporation or self-directed pension plan, 2) research grants, 3) employment (full or part time), 4) ownership or partnership, 5) consulting fees or other remuneration received by the presenter or his/her immediate family, including support that may be provided to attend the educational meeting, 6) nonremunerative positions of influence such as officer, board member, trustee, or public spokesperson. The disclosure will be shown as an indication (by an *) for those presenters who have stated that a relationship(s) exists relevant to the topic(s) being discussed.

8. Indicate any author(s) who has a possible conflict of interest (see Policy Statement) by an asterisk (*) next to that author(s) name in the heading of the abstract.

Submitting Author 
Signature (Printed Form Only) ___________________
9. Please indicate if you prefer a poster presentation.
I would prefer a poster presentation.
10. Select one category, under which your abstract will be reviewed:
  1. Molecular cardiology, Basic research
  2. Vascular biology, Basic research
  3. Pharmacologic modulation of vascular-endothelial function
  4. Genetic determinants of coronary heart disease/cardiomyopathies
  5. Gene transfer and therapy
  6. Biochemical markers of acute ischemia
  7. Contrast echocardiography
  8. Pharmacologic stress testing - Echocardiography
  9. Echocardiography: TEE and 3-D
  10. Nuclear Cardiology
  11. PET/MRI/CT
  12. Other diagnostic methods: Percutaneous coronary angioscopy / intravascular ultrasound imaging /intracoronary flow, doppler measurements
  13. The plaque and acute coronary syndromes
  14. Myocardial stunning, Hibernation and preconditioning
  15. Acute myocardial infarction: thrombolysis and reperfusion
  16. Angioplasty therapy for acute MI
  17. Stents: new devices/optimal application/multiple stents
  18. Antithrombotic and antiplatelet adjunctive therapy for PTCA
  19. Blockade of tissue proliferation after coronary interventions
  20. Restenosis - use of ionizing radiation
  21. Nitrates, beta blockers, calcium entry blockers and ACE inhibition drugs for ischemic heart disease
  22. Left ventricular remodeling after MI
  23. Secondary prevention, prognosis, risk stratification, cardiac rehab
  24. Modification of lipoproteins and coronary disease
  25. Hypertension, basic and clinical
  26. Diabetes mellitus, obesity, insulin and atherosclerosis
  27. Primary prevention of coronary artery disease in the healthy adult and children
  28. Hormone therapy in postmenopausal women
  29. Natriuretic peptides, endothelin: role in heart failure
  30. Neurohumoral, immunologic and cytokine aspects of heart failure
  31. Nitric oxide and nitric oxide synthase in heart failure
  32. Myocyte and receptor abnormalities in heart failure
  33. Dilated cardiomyopathy: various etiologies
  34. Left ventricular hypertrophy and hypertrophic cardiomyopathy
  35. Role of the pericardium - basic and clinical
  36. Pulmonary circulation aspects, pulmonary hypertension
  37. Predictors and markers of heart failure outcome
  38. Exercise physiology in heart failure
  39. Renal aspects - diuretics
  40. Digoxin and other new inotropic agents in heart failure
  41. ACE inhibitors and Angiotensin-ll receptor blockers
  42. Organic nitrates-their role in heart failure management
  43. Beta-blockers and beta-adrenergic receptors in heart failure
  44. Calcium channel blockers and promoters in heart failure
  45. Arrhythmias and antiarrhythmic drug therapy - basic and clinical
  46. Sudden death
  47. Electrophysiologic techniques of mapping and radiofrequency ablation
  48. Internal defibrillation/implantable antiarrhythmic devices/pacing
  49. Pediatric cardiology and cardiac surgery/congenital heart disease
  50. Angioplasty or surgery for multivessel coronary artery disease
  51. New approaches to surgical revascularization: minimally invasive surgery, TMLR
  52. Valvular heart disease/Heart valve surgery-adult
  53. Mechanical support left ventricular assist devices
  54. Surgery for LV dysfunction
  55. Cardiac transplantation
  56. Practice guidelines, cost containment
  57. Computers in cardiology
  58. Miscellaneous

Please state below the name and address of the presenting author:

ON-LINE ABSTRACT FORM
Fields in red are required.

First Name:
Middle Initial(s):
Family Name:
Title:
Department:
Institution:
Mailing Address:
Street Address:
Suite/Apt.:
City:
State/Province:
Country:
Postal Code:
Tel: (office hours) Country code/city code/number
Fax: Country code/city code/number
E-Mail:
Title of Abstract: (CAPITAL LETTERS)
Type of abstract:
Please list all co-authors [first name, middle initial(s) and last name]  in the order they should appear in all publication.
Co-Authors 
No. First Name Middle Initial(s) Last Name
1
2
3
4
5
6
7
8
9
10
Institution, city, country where the research was preformed
Abstract

 

ATARTICA WEB DESIGN ©